title: A two-phase, retrospective analysis evaluating efficacy of and patient satisfaction with abobotulinumtoxina used to treat dynamic facial rhytides.
abstract: BACKGROUND
  Numerous studies on cosmetic uses of the two major forms of botulinum type A toxin-onabotulinumtoxinA and abobotulinumtoxinA--have been reported, but there is a lack of published, non-industry-funded data regarding efficacy and patient satisfaction with abobotulinumtoxinA. OBJECTIVES To evaluate the efficacy of and patient satisfaction with abobotulinumtoxinA injections.
  
  
  METHODS
  Retrospective, two-phase study of 185 patients treated with abobotulinumtoxinA for dynamic facial rhytid reduction over an 8-month period. Data were gathered using chart review and patient follow-up.
  
  
  RESULTS
  The average total amount of abobotulinumtoxinA injected per visit was similar in each phase (93.7 U in phase I, which used a ratio of 2.5 abobotulinumtoxinA units to 1 onabotulinumtoxinA unit, and 99.6 U in phase II, which used a ratio of 3:1). Of patients with a history of onabotulinumtoxinA injections (89.1% in phase I and 91% in phase II), the majority preferred onabotulinumtoxinA. A similar percentage in each group reported overall satisfaction with abobotulinumtoxinA (70.9% in phase I and 68% in phase II).
  
  
  CONCLUSIONS
  Although generally satisfied with abobotulinumtoxinA, when given a choice between abobotulinumtoxinA and onabotulinumtoxinA, the majority of patients favored the latter. This preference remained even after the dilution of abobotulinumtoxinA was decreased.
authors.affiliation: Dermatology Cosmetic Laser Associates of La Jolla, San Diego, California, USA.
authors.forename: Monika G
authors.initials: MG
authors.lastname: Kiripolsky
authors.forename: Jennifer D
authors.initials: JD
authors.lastname: Peterson
authors.forename: Isabella
authors.initials: I
authors.lastname: Guiha
authors.forename: Mitchel P
authors.initials: MP
authors.lastname: Goldman
mesh_terms: D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D005145:Face; D006801:Humans; D007267:Injections; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D017060:Patient Satisfaction; D015595:Skin Aging; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA